Botulinum toxin A topical - Revance Therapeutics

Drug Profile

Botulinum toxin A topical - Revance Therapeutics

Alternative Names: BoNTA; DaxibotulinumtoxinA Topical gel; RT 001 - Revance; RT-001

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Revance Therapeutics
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Migraine
  • Preclinical Neuropathic pain
  • Discontinued Facial-wrinkles; Hyperhidrosis

Most Recent Events

  • 04 Aug 2016 Revance Therapeutics has patent protection for botulinum toxin-related applications
  • 01 Aug 2016 Revance Therapeutics completes the phase III REALISE 1 trial in Facial wrinkles in USA (NCT02580370)
  • 13 Jun 2016 Discontinued - Phase-II for Hyperhidrosis in USA as the phase III Realise 1 trial failed to achieve its primary endpoint (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top